S
Sphere Bio
Enabling rapid screening and characterisation of single cells
About Sphere Bio
Sphere Bio is a life sciences company that has developed a platform for single-cell analysis and isolation based on its proprietary picodroplet microfluidic technology. The company's flagship product, the Cyto-Mine® Chroma, is a fully automated system that can encapsulate, analyze, sort, and dispense viable single cells at high throughput.
Read full description
This technology is particularly applicable in the fields of cell-based therapy and synthetic biology. For cell-based therapies, the platform allows for the characterization of individual cells, which is a critical step in ensuring the safety and efficacy of these treatments. In synthetic biology, the high-speed nature of picodroplets is well-suited for the rapid screening and evolution of engineered cells.
Sphere Bio's business model involves the sale of its Cyto-Mine® Chroma instrument and the associated consumables. The company serves a global market through a direct sales force and a network of distributors. Its client base consists of research institutions, pharmaceutical companies, and biotechnology firms engaged in cell-based research and development.
At a glance
- Status
- Operational
- Founded
- 2010
- Headquarters
- Cambridge, United Kingdom
- Employees
- 24
- Open positions
- None listed
- Dealroom signal
- 60.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, uk rio, Microfluidics, rio engineering biology, Genetics and genomics, Stem Cells, rio Synbio in Life Sciences, Screening, Enzymes, Immune System, Synthetic Biology
Latest news
Press, funding announcements and product moves mentioning Sphere Bio.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Jan 2023 | $964K | — | Undisclosed | — |
| LATE VCOther financing | Oct 2021 | $40M | $160M | Sofinnova Partners · Redmile Group | — |
Growth signals
Latest recorded traffic for Sphere Bio is 4.1K monthly website visits, up 70.8% over the last three months. Sphere Bio's team declined 14.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Twist Bioscience
Series A5 investors entered at this stage
Parkwalk Advisors
Newable Private Investing
QVentures- GCGreenwood Way Capital
Oxford Technology
Series B and later4 investors entered at this stage
24Haymarket
London Business Angels
Redmile Group
Sofinnova Partners
Other known investors2 additional known investors
Cambridge Enterprise
University of Cambridge
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sphere Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sphere Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.